trial · primary record
Selinexor
Gliosarcoma
| Phase | Phase 1 |
|---|---|
| Status | COMPLETED |
| Sponsor | Unknown |
| Enrolment | 11 |
| Primary completion | 2026-07-09 |
| Primary endpoint | Maximum Tolerated Dose (MTD) of Selinexor |
| Registry ID | NCT04216329 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:32:36.516Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT04216329
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.